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Variceal hemorrhage is a major cause of death in patients with cirrhosis. Over the past two decades new treatment modalities have
been introduced in the management of acute variceal bleeding (AVB) and several recent studies have suggested that the outcome
of patients with cirrhosis and AVB has improved. Improved supportive measures, combination therapy which include early use of
portal pressure reducing drugs with low rates of adverse eﬀects (somatostatin, octerotide or terlipressin) and endoscopic variceal
ligation has become the ﬁrst line treatment in the management of AVB. Short-term antibiotic prophylaxis, early use of lactulose
for prevention of hepatic encephalopathy, application of early transjugular intrahepatic portasystemic shunts (TIPS), fully covered
self-expandable metallic stent in patients for AVB may be useful in those cases where balloon tamponade is considered. Early and
wide availability of liver transplantation has changed the armamentarium of the clinician for patients with AVB. High hepatic
venous pressure gradient (HVPG) >20mmHg in AVB has become a useful predictor of outcomes and more aggressive therapies
with early TIPS based on HVPG measurement may be the treatment of choice to reduce mortality further.
1.Introduction
Portal hypertension (PHT) worsens with increasing severity
of cirrhosis and is responsible for many of its complications,
which lead to clinical decompensation. The prevention and
treatment of these complications have therefore been a
cornerstone of the management of the patient with cirrhosis.
Gastroesophageal varices are present in 50% of patients with
cirrhosis, and variceal hemorrhage develops in up to one-
thirdofthesepatients[1–3].Theinitialappearanceofvarices
in patients with compensated cirrhosis indicates a progres-
sion of the disease from a low-risk state to an intermediate
one. Once bleeding occurs, this indicates decompensation
and progression to a high risk of death [4, 5]. The risk of
variceal hemorrhage is increased in patients who have large
varicesandadvancedstagesofliverdisease,asassessedonthe
basis of the Child-Pugh class [6, 7]. Several studies published
between 1942 and 1981 showed poor outcomes after variceal
hemorrhage, with mortality rates of 40% at 6 weeks and 70%
at 1 year [4, 8–11]. Over the past ﬁve decades, a number of
randomized trials have shown an improvement in the eﬃ-
cacy of endoscopic, pharmacologic, surgical, and radiologic
techniques for arresting hemorrhage [12–14]. Subsequently,
retrospective single-center and multicenter studies have
shown a decrease in hospital mortality associated with
variceal hemorrhage over the past two decades [14–19].
In a study by Chalasani et al. [14] a total of 231 subjects
were included, and their in-hospital, 6-week, and overall
mortality rates were 14.2%, 17.5%, and 33.5%, respectively.
The mortality rate after variceal bleeding in this study was
substantially lower than previously reported. This suggests
that advances made in the management of variceal bleeding
have improved outcomes after variceal bleeding. Similarly
Carbonell et al. [12] reviewed the clinical records of all
patients with cirrhosis due to variceal bleeding during the
years 1980, 1985, 1990, 1995, and 2000. Whereas balloon
tamponade was still the ﬁrst-line treatment in 1980, patients
treated in 2000 received a vasoactive agent, an endoscopic
treatment, and an antibiotic prophylaxis in, respectively,
90%, 100%, and 94% of cases. The in-hospital mortality
rate steadily decreased over the study period: 42.6%, 29.9%,
25%, 16.2%, and 14.5% in 1980, 1985, 1990, 1995, and
2000, respectively (P<. 05). Mortality decreased from
9% in 1980 to 0% in 2000 in Child-Turcotte-Pugh class
A patients, from 46% to 0% in class B patients, and from
70% to 32% in class C patients. This improved survival2 International Journal of Hepatology
Table 1: Antibiotics compared to placebo in acute variceal bleed.





P versus A eﬃcacy





34 30 53% versus 13% A>P
Soriano et al. [30] Bacterial
infection Norﬂox 59 60 10% versus 37% A>P
Hsieh et al. [28] Bacterial
infection ciproﬂoxacin 60 60 45% versus 10% A>P
Jun et al. [29] Bacterial
infection Cefotaxime 62 58 16% versus 3% A>P
Table 2: Antibiotics preventing mortality in acute variceal bleed.
Author Outcome Drug Drug Relative risk CI
Gulberg et al. [34] Bacterial infection Ceftriaxone 1gm (1/40) Ceftriaxone 2gm (1/42) 1.05 0.11–9.80
Lata et al. [35] Mortality Ampicillin and sulbactam 3g (12/21) Norﬂoxacin 800mg (7/25) 2.04 0.98–4.23
Fern´ andez et al. [36] Mortality Ceftriaxone 1g (8/54) Norﬂoxacin 800mg (6/57) 1.41 0.52–3.79
was associated with a decrease of rebleeding (from 47% in
1980 to 13% in 2000) and bacterial infection rates (from
38% to 14%). On multivariable analysis, endoscopic therapy
and antibiotic prophylaxis were independent predictors of
survival. Thomopoulos et al. [18] studied 141 patients with
acute variceal bleed and found 6-week, 1-year, and overall
mortalitywere12.1%,18.4%,32.6%and48.2%,respectively.
The rate of recurrent bleeding was 10.7% during initial
hospitalisation.BeingChild-PughC(P = .003)andshockon
admission(P = .037)wereindependentpredictorsof6-week
mortality, while being Child-Pugh C (P = .028), presence
of hepatocellular carcinoma or other neoplasia (P = .04),
andpartialthromboplastintime(P = .021)duringtheinitial
admission were independent predictors for 1-year mortality.
Mortality was not aﬀected by the presence of active bleeding
and/or white nipple at emergency endoscopy. Also presence
of infection was not an adverse factor of clinical outcome in
our patients. In all these studies the decrease in mortality
was largely due to improvement in general measures, more
eﬀective endoscopic therapy in combination with vasoactive
medications, prevention of sepsis through the use of antibi-
otic prophylaxis, and the prevention of rebleeding.
2. Improvement in General Measures
There is evidence that current treatment strategies for acute
variceal hemorrhage, including general and speciﬁc mea-
sures, have resulted in an improved survival [12, 18]. Initial
resuscitation by multidisciplinary team involves basic mea-
sures including assessing the patient’s airway and obtaining
peripheral venous access. Blood volume resuscitation should
be undertaken promptly but with caution, with the goals
of maintaining hemodynamic stability and a hemoglobin of
approximately 7-8g/dL [19, 20]. This recommendation is
basedonexperimentalstudiesthatshowthatrestitutionofall
lostbloodleadstoincreasesinportalpressuretolevelshigher
than baseline [21] and to more rebleeding and mortality
[22]. Similarly, vigorous resuscitation with saline solution
should generally be avoided because, in addition to possibly
precipitating recurrent variceal hemorrhage, this can worsen




Currently, it is recommended that short-term antibiotic
prophylaxis, a measure that reduces bacterial infections [23],
variceal rebleeding, and death [24], be used in every patient
with cirrhosis admitted with gastrointestinal hemorrhage
[20, 25, 26]. Diﬀerent antibiotics have been used in diﬀerent
trials compared with placebo (Table 1,[ 27–30]). Bacterial
infection is commonly associated with variceal hemorrhage
and appears to be an independent risk factor for failure
to control bleeding [31] and predicts both early rebleeding
and death [32, 33]. The routine use of prophylactic broad-
spectrum antibiotics has shown a marked improvement in
outcome in acute variceal hemorrhage. Routine intravenous
ceftriaxone or postendoscopic norﬂoxacin reduces rebleed-
ing rates compared to on-demand antibiotics (Table 2)[ 24,
29, 34–36]. A Cochrane meta-analysis of antibiotic pro-
phylaxis in cirrhotic patients with gastrointestinal bleeding
involving 12 trials with 1241 patients evaluated antibiotic
prophylaxis compared with placebo or no antibiotic pro-
phylaxis. Antibiotic prophylaxis compared with no inter-
vention or placebo was associated with beneﬁcial eﬀects on
mortality (RR 0.79, 95% CI 0.63 to 0.98), mortality from
bacterial infections (RR 0.43, 95% CI 0.19 to 0.97), bacterial
infections (RR 0.36, 95% CI 0.27 to 0.49). They concluded
that prophylactic antibiotic use in patients with cirrhosisInternational Journal of Hepatology 3
and upper gastrointestinal bleeding signiﬁcantly reduced
bacterial infections, and seems to have reduced all-cause
mortality, bacterial infection mortality, rebleeding events,
and hospitalisation length. These beneﬁts were observed
independently of the type of antibiotic used [37, 38]. The
rationale behind the oral administration of norﬂoxacin, a
poorly absorbed quinolone, is the selective eradication (or
at least reduction) of Gram-negative bacteria in the gut,
the source of bacteria. However, quinolone antibiotics with
similar spectrum of activity, such as ciproﬂoxacin, could also
be recommended. When oral administration is not possible,
quinolones can be administered intravenously (IV). In a
recent study performed in patients with advanced cirrhosis
(ChildB/C)andGIhemorrhage,IVceftriaxone(1g/day)was
more eﬀective than oral norﬂoxacin in preventing bacterial
infections mostly those due to Gram-negative organisms
[36]. It has now become standard practice to administer
prophylactic antibiotics in acute variceal hemorrhage and
in cirrhotic patients with gastrointestinal bleeding of any
cause. The clear survival beneﬁt associated with prophylactic
antibiotics in gastrointestinal hemorrhage associated with
cirrhosis is not in doubt. Both American and British guide-
lines recommend the administration of antibiotics prior to
endoscopy in patients with AVB [39, 40].
4 .U s eo fN e w e rP h a rm a c o l ogi cT r ea tm e n ti n
Reducing Mortality
Pharmacological therapy has the advantages of being gen-
erally applicable and capable of being initiated as soon as
a diagnosis of variceal hemorrhage is suspected, even prior
to diagnostic EGD [20, 25, 26]. Newer development of
d r u g sl i k es o m a t o s t a t i na n da n a l o g u e ss u c ha so c t r e o t i d e
and vapreotide also causes splanchnic vasoconstriction at
pharmacological doses due to an inhibition of the release
of vasodilatory peptides mainly glucagon. The advantage
of somatostatin and analogues such as octreotide and
vapreotide is that they are safe and can be used continuously
for 5 days or even longer [20].
However, results of meta-analysis of trials of octreotide
are controversial [41, 42]. In a recent metaanalysis twenty
studies were identiﬁed for all the comparison groups that
indicates that terlipressin was associated with a statistically
signiﬁcant reduction in all-cause mortality compared to
placebo (relative risk 0.66, 95% conﬁdence interval 0.49
to 0.88). There was no signiﬁcant diﬀerence between the
terlipressin group and any of the comparison groups in the
number of adverse events that caused death or withdrawal of
medication. On the basis of a 34% relative risk reduction in
mortality, terlipressin should be considered to be eﬀective in
the treatment of acute variceal hemorrhage [43].
Endoscopictherapywitheitherbandligationorinjection
sclerotherapy is an integral component of the management
of acute variceal bleeding and of the long-term treatment of
patients after a variceal bleed. Regarding the best endoscopic
therapy, a metaanalysis of 10 randomized controlled trials
including 404 patients shows an almost signiﬁcant beneﬁt
of EVL in the initial control of bleeding compared to
sclerotherapy (pooled relative risk of 0.53 with a conﬁdence
interval of 0.28–1.01) [44]. Variceal eradication with endo-
scopic ligation requires fewer endoscopic treatment sessions
and causes substantially less esophageal complications than
does injection sclerotherapy. Although the incidence of early
gastrointestinal rebleeding is reduced by endoscopic ligation
in most studies, there is no overall survival beneﬁt relative to
injection sclerotherapy.
In a recent metaanalysis pharmacotherapy is found to be
as eﬀective as emergency sclerotherapy in patients with acute
variceal bleed. Seventeen trials including 1817 patients were
identiﬁed. No signiﬁcant diﬀerences were found comparing
sclerotherapy with each vasoactive drug for any outcome.
Combining all the trials irrespective of the vasoactive drug,
the risk diﬀerences (95% conﬁdence intervals) were failure
to control bleeding −0.02 (−0.06 to 0.02), ﬁve-day failure
rate −0.05 (−0.10 to 0.01), rebleeding 0.01 (−0.03 to 0.05),
mortality(17randomisedtrials,1817patients) −0.02(−0.06
to 0.02), and transfused blood units (8 randomised trials,
849 patients) (weighted mean diﬀerence) −0.24 (−0.54 to
0.07). Adverse events 0.08 (0.03 to 0.14) and serious adverse
events 0.05 (0.02 to 0.08) were signiﬁcantly more frequent
with sclerotherapy [45].
5. CombinationTherapyasStandardofTherapy
Combination of both pharmacologic and endoscopic ther-
apy in the treatment of AVB is strongly supported by
numerous trials showing that the eﬃcacy of both emergency
EST and EBL is signiﬁcantly improved when they are associ-
ated with pharmacologic treatment [41, 46]. Although both
methods are highly eﬀective in controlling AVB, EBL has
become the treatment of choice both for controlling variceal
hemorrhage and for variceal obliteration in secondary
prophylaxis [20, 26]. A meta-analysis has shown that EBL
is better than EST for all major outcomes including initial
control of bleeding, recurrent bleeding, side eﬀects, time to
variceal obliteration, and survival [47]. Thus, combination
therapy with a vasoactive drug plus EBL is considered the
standard of care for AVB, and it is currently recommended
by guidelines [20]. Combination therapy improves the 5-
day success rate compared with endoscopic ligation therapy
alone [48, 49], but this is not associated with any diﬀerences
in mortality. Given these reasons, EBL at present is the
endoscopic method of choice to treat esophageal varices in
most cases. However, EST is an accepted method if EBL
cannot be performed.
6. Evaluation of Hepatic Venous
Pressure Measurement in Patient with
AcuteVaricealBleed
Assessment of portal pressure by the hepatic venous pressure
gradient (HVPG) has been a useful predictor of outcomes
in both stages. In patients with compensated cirrhosis, an
HVPG greater or equal to 10mmHg is the most important
predictor of the development of varices and clinical decom-
pensation [50, 51]. Prospective cohort studies in which4 International Journal of Hepatology
HVPG has been measured within 48 hours of admission
for hemorrhage show that levels greater than 20mmHg are
associated with increased rebleeding and mortality [52–54].
A more recent study performed in the era of combined
vasoactivedrugplusendoscopictherapyconﬁrmsthisHVPG
cutoﬀ and shows that an index including CTP score and
blood pressure at admission has similar prognostic value
[55]. Furthermore, a drug-induced HVPG reduction of less
than 10% predicts 5-day failure. This response may improve
by doubling the dose of somatostatin or switching to another
agent (such as terlipressin).
In acute complications of cirrhosis, such as variceal
bleeding, there have been fewer studies of portal pressure,
but, also in this setting, HVPG has been shown to be
prognosticforbothsurvivalandthecourseofbleeding.Vinel
etal.[56]documentedthatshort-termprognosisinalcoholic
cirrhotic patients with variceal bleeding was independently
associated with portohepatic gradient measured within 48h
of admission. This was conﬁrmed in a small study of 22
patients, in which the best cutoﬀ for continued bleeding
or early rebleeding was HVPG >16mmHg [53]. Villanueva
et al. [57] showed that HVPG > 20mmHg and a decrease
<10mmHg under vasoactive therapy were independent
predictors of further bleeding. An HVPG > 20mmHg has
been shown to correlate with important clinical outcomes
such as more diﬃculty in controlling acute variceal bleeding,
more early rebleeding, more blood transfusion need, more
days in intensive care and increased hospital mortality
[58]. Lastly Avgerinos et al. [59] showed that HVPG >
16mmHg was independently associated with death and/or
early rebleeding evaluating HVPG measurements before and
immediately after endoscopic treatment and every 24h for a
5-day period.
7.TransjugularIntrahepaticPortosystemic
Shunt in Acute Variceal Hemorrhage
Transjugular intrahepatic portosystemic shunt (TIPS) is a
reasonable alternative in the face of failure of combined
pharmacologic plus endoscopic therapy. In the Baveno
conference, it was considered that a second attempt at
endoscopic therapy was one possibility but that one could
perform TIPS after failure of the ﬁrst endoscopic therapy.
An elevated hepatic venous pressure gradient (>20mm Hg)
measured within 24 hours after the start of bleeding is the
best predictor of treatment failure [26]. The use of TIPS
to control variceal bleeding has largely been reserved for
patients who require rescue therapy because hemostasis has
notbeenachieved,eitherduringtheindexbleedingorduring
thesecondary-prophylaxisperiod.TIPSisextremelyeﬀective
in controlling bleeding, with a reported rate of immediate
hemostasis of 93% and with rebleeding in only 12% of
patients. Nevertheless, mortality at 6 weeks among patients
treated with rescue TIPS for uncontrolled index bleeding
and rebleeding is very high (35%), reﬂecting the severity
of their underlying liver disease as well as additional organ
dysfunction that may have occurred owing to hypotension,
infection, and aspiration [60].
Recently Garc´ ıa-Pag´ an and colleagues report the results
of a randomized, multicenter study that compared early
TIPS with optimal medical therapy (endoscopic therapy plus
vasoactive drugs) in patients at high risk for rebleeding who
were either in Child-Pugh class B with active bleeding at
endoscopy or in Child-Pugh class C. This study shows the
beneﬁt of early TIPS in patients with Child-Pugh class B or C
disease who-are at high risk for uncontrolled bleeding with
standard therapy. Patients who were randomly assigned to
receive TIPS had a signiﬁcantly better chance of remaining
freeofbleedingthandidthosewhoreceivedthestandardcare
(97% versus 50%), possibly owing to a greater reduction in
portal pressure with TIPS than could be achieved with phar-
macologictherapy.Therateofsurvivalat6weekswas97%in
theTIPSgroupascomparedwith67%inthemedicaltherapy
group, as a result of reductions in rebleeding, sepsis and liver
failure [61]. Use of the newer stents, which are covered with
extended polytetraﬂuoroethylene (e-PTFE), probably has an
important bearing on the outcome of this study [15].
8.Newer Methods
The recent introduction of a fully covered self-expandable
metallic stent for AVB may be useful in those cases where
balloon tamponade is considered. The stent is placed over
a guide wire previously passed to the stomach. The stent
has a distal balloon that is inﬂated with a syringe to ensure
proper location in the cardias and lower esophagus so no
ﬂuoroscopy is needed. The stent can be left in place for up
to 14 days, and it can be retrieved by endoscopy with a hook
system. There are limited data with its use. A pilot study of
20 patients who failed standard of care treatment reported
100% success without any signiﬁcant complications [62].
9. Summary
AVB is a dreaded complication of patients with portal
hypertension. Initial management includes appropriate vol-
ume replacement, transfusion of blood to keep hemoglobin
levels at 7-8g/L, antibiotic prophylaxis, and endotracheal
intubation in selected cases. Standard of care mandates for
earlyadministrationofvasoactivedrugtherapyandthenEBL
or injection ES (if EBL cannot be performed) within the
ﬁrst 12 hours of the index bleed. The use of pharmacologic
agents may be prolonged for up to 5 days. Patients who
fail endoscopic therapy may require temporary placement
of balloon tamponade or stents. All patients surviving an
episode of AVB should undergo further prophylaxis to
prevent rebleeding. However, despite the application of these
gold-standard treatments, 10% to 15% of cirrhotic patients
still have treatment failure. Despite the high success of
rescue TIPS in controlling bleeding in treatment failures, the
mortality of patients in whom the initial approach failed
is high due to liver failure. It is possible that in the near
future, patients may be treated “´ a la carte.” Indeed, in high-
riskpatients,moreaggressivetherapieswithearlyPTFETIPS
based on HVPG measurement may be the treatment of
choice to reduce mortality further.International Journal of Hepatology 5
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